First day of trading in Curasight’s shares and warrants at Spotlight Stock Market
October 8, 2020
Today is the first day of trading in Curasight A/S ("Curasight") shares and warrants of series TO 1. Curasight’s shares are traded under the ticker "CURAS" with ISIN DK0061295797 and Curasight’s warrants of series TO 1 are traded under the ticker "CURAS TO 1" with ISIN DK0061408747.
Prolongation and expansion of agreement with TRT Innovations ApS
October 7, 2020
Today, the 7 October, 2020, Curasight A/S (“Curasight” or the “Company”) has entered into an expansion of the agreement with TRT Innovations ApS (“TRT Innovations”), which ensures the right for the Company to broaden its activities within targeted radionuclide therapy in cancer.
Significantly oversubscribed IPO of units in Curasight
September 22, 2020
The subscription period for Curasight A/S ("Curasight") IPO of units (shares and consideration free warrants) ended on September 17[th] 2020. The initial part of the IPO of units was subscribed to a total of approx. DKK 273 million, corresponding to a subscription ratio of approx. 835 percent, and Curasight will thereby be provided approx. DKK 32.7 million (before issue costs) through the IPO of units. Through the issue of units, Curasight receives approx. 1,700 new shareholders. In addition to the IPO of units, the company has executed a directed issue of units to the same terms as the IPO, which will provide Curasight with an additional approx. DKK 14 million (before issue costs). Settlement notes are scheduled to be sent out today, September 22[nd], 2020. Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor in connection with the capitalization and listing.
Webcast with Curasight
September 9, 2020
Curasight A/S CEO Ulrich Krasilnikoff and CSO Andreas Kjaer presented the company, its operations and future plans, via a webcast together with Biostock. See below for more information.
The subscription period in Curasight’s issue of units starts today
September 3, 2020
Today, the 3[rd] of September, 2020, the subscription period for Curasight A/S ("Curasight") issue of units (shares and consideration free warrants) begins. The subscription period runs until the 17[th] of September 2020. A fully subscribed issue of units will initially provide Curasight with approximately DKK 32.7 million (before issue costs) and an additional approximately DKK 34.2 million (before issue costs) at a later stage if all warrants are exercised. Prior to the commencement of the issue of units, Curasight has received subscription commitments from, among others, senior executives and board members. In total, the subscription commitments correspond to approx. 79 percent of the inital issue volume. Prospectus, teaser and subscription forms are available through the websites of Curasight (www.curasight.com) and Sedermera Fondkommission (www.sedermera.se). The investment documents are also available via Spotlight’s website (www.spotlightstockmarket.com). Sedermera Fondkommission is the financial advisor in the transaction and Markets & Corporate Law Nordic AB is the legal adviser.
Curasight A/S receives approval for listing and publishes prospectus
September 2, 2020
Today, Curasight A/S (“Curasight”) announces that the company has received approval for listing at Spotlight Stock Market. The approval is given under the condition that the company raises the minimum limit and that the company obtains a sufficient number of shareholders in accordance with Spotlight Stock Market’s listing agreement in the upcoming IPO. Curasight today also publishes the prospectus for the upcoming issue of units, for which the subscription period starts on Thursday, the 3[rd] of September 2020, and ends on the 17[th] of September 2020. The prospectus is available at Curasight’s website (www.curasight.com), Sedermera Fondkommission’s website (www.sedermera.se) and the website of Spotlight Stock Market (www.spotlightstockmarket.com). Teaser and subscription form will be published on the webpages mentioned above at the start of the subscription period.